Abstract Neuroendocrine (NE) lung tumors comprise 20-25 % of all invasive lung malignancies. Currently, no effective treatments are available to cure these tumors, and it is necessary to identify a molecular alteration(s) that characterizes NE lung tumor cells. We aimed to identify a kinase mutation(s) associated with NE lung tumor by screening 517 kinase-encoding genes in human lung cancer cell lines. Our next-generation sequencing analysis of six NE lung tumor cell lines (four small cell lung cancer lines and two non-small cell lung cancer lines) and three non-NE lung tumor lines revealed various kinase mutations, including a nonsynonymous mutation in the proto-oncogene RET (c.2071G [ A; p.G691S). Further evaluation of the RET polymorphism in total 15 lung cancer cell lines by capillary sequencing suggested that the frequency of the minor allele (A-allele) in NE lung tumor lines was significantly higher than its frequency in a reference population (p = 0.0001). However, no significant difference between non-NE lung tumor lines and a reference group was detected (p = 1.0). Nevertheless, neither RET expression levels were correlated with the levels of neuron-specific enolase (NSE), a key NE marker, nor vandetanib and cabozantinib, small molecule compounds that inhibit RET, affected NSE levels in lung cancer cells. Our data suggest a potential association of G691S RET polymorphism with NE lung tumor, proposing the necessity of more thorough evaluation of this possibility. The dataset of kinase mutation profiles in this report may help choosing cell line models for study of lung cancer.
Introduction
Lung cancer is currently the most common cancer worldwide, comprising nearly 13 % of new cancer cases each year and being the leading cause of cancer mortality (Jemal et al. 2011; Siegel et al. 2012) . Lung cancers are mainly classified as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which account for approximately 87 and 13 % of all lung cancer cases, respectively (Govindan et al. 2006) . Lung cancers are also divided into various subtypes according to their different characteristics (Govindan et al. 2006; Herbst et al. 2008) . For example, neuroendocrine (NE) phenotypes characterize a spectrum of lung tumors from the low grade typical carcinoid and intermediate grade atypical carcinoid to the high grade large cell NE carcinoma and SCLC (Rekhtman 2010; Travis 2009; van Meerbeeck et al. 2011) . NE lung tumors comprise 20-25 % of all invasive lung malignancies, among which SCLC is the major whereas carcinoid tumors and large cell NE carcinomas are the minor (Swarts et al. 2012; Travis 2009 ). Multiple studies have revealed various genetic alterations in non-NE lung tumors, including adenocarcinoma and squamous cell lung carcinoma (Bergethon et al. 2012; Dutt et al. 2011; Hammerman et al. 2011; Kohno et al. 2012; Lipson et al. 2012; Pao et al. 2004; Soda et al. 2007; Takeuchi et al. 2012) . However, such information on NE lung tumors is relatively limited, demanding identification of genetic alterations associated with NE lung tumors.
The proto-oncogene rearranged during transfection (RET) encodes a receptor tyrosine kinase, which is activated by glial cell line-derived neurotrophic factor (Asai et al. 2006 ). While RET is essential for early development of the enteric nervous system and the kidney, and for spermatogenesis, different mutations in RET are associated with several human tumors with NE characteristics (de Groot et al. 2006) . For example, multiple endocrine neoplasia type 2A (MEN2A), MEN2B and familial medullary thyroid carcinomas are attributed to the germline mutations that constitutively activate RET (Plaza Menacho et al. 2005; Santoro et al. 1995) . Certain RET polymorphisms have also been characterized for their additive effects. For example, it was reported that RET L769L and S836S single nucleotide polymorphisms (SNP) are associated with increased risks of sporadic medullary thyroid carcinoma (Ceolin et al. 2012) . It was also reported that the G691S SNP in RET exon 11 (rs1799939; c.2071G [ A) may have a functional role as a genetic modifier in MEN2A (Robledo et al. 2003) , medullary thyroid carcinoma (Cardot-Bauters et al. 2008; Elisei et al. 2004; Lantieri et al. 2012) , desmoplastic melanoma (Barr et al. 2012; Narita et al. 2009) , and pancreatic cancer (Sawai et al. 2005) . RET mutations have also been reported in lung cancer, albeit not frequently. For example, a single somatic point mutation in RET (A664D in the juxta-membrane domain) was detected in two of seven SCLC specimens, although its functional significance is yet unclear (Futami et al. 1995) . Allelic loss of the RET locus was also detected in SCLC patients (Futami et al. 2003 ). In addition, recent studies detected the RET gene fusions, i.e., KIF5B-RET and CCDC6-RET, in about 2 % of lung adenocarcinoma patients (Kohno et al. 2012; Lipson et al. 2012; Takeuchi et al. 2012) , and several somatic RET mutations, including R820L in the kinase domain, and A1051T in the cytoplasmic domain in SCLC patients Rudin et al. 2012) . Therefore, RET may be involved in lung tumorigenesis. Nevertheless, RET mutations that characterize NE lung tumor have not been reported.
Human genome encodes 518 protein kinases, and deregulation of many kinases has been established as a major mechanism for cancer development (Taylor and Kornev 2011) . In this study, we conducted kinome sequencing of nine human lung cancer lines to identify genetic alterations that may characterize NE lung tumor. Our study reveals various kinase mutations, including those that were previously reported. Further, we detected relatively high occurrence of G691S RET variant in lung cancer lines, specifically in lines with NE phenotype, suggesting a potential association of the G691S RET polymorphism with NE lung tumor.
Materials and methods

Cell culture and reagents
Human SCLC cell lines (DMS53, NCI-H209, NCI-H69, SHP77, NCI-H889, NCI-H345, and NCI-H82) and human NSCLC cell lines (A549, NCI-H23, NCI-H460, NCI-H1155, NCI-H358, NCI-H727, NCI-H1770, and NCI-H125) were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10 % fetal bovine serum, and 1 % penicillin streptomycin, as previously described . All SCLC and the two NSCLC lines, NCI-H1155 and NCI-H727, were previously characterized as NE tumors (Carney et al. 1985; Gazdar and Minna 1996; Linnoila 1996) . Human primary diploid fibroblasts IMR90 were maintained in MEM (Invitrogen, Carlsbad, CA) supplemented with 10 % bovine growth serum, 1 % sodium pyruvate, 1 % MEM non-essential amino acids, and 1 % penicillin streptomycin. Vandetanib was purchased from Invitrogen and LC Laboratories (Woburn, MA). Cabozantinib was purchased from Selleckchem (Huston, TX).
Genomic DNA extraction
Genomic DNA was extracted using PureLink Genomic DNA Kit (Invitrogen) according to the manufacture's protocol. The concentration of DNA and its high quality (A 260/280 of 1.8-2) were determined using the NanoVue Plus spectrophotometer (GE Healthcare Biosciences, Pittsburgh, PA).
Kinome sequencing 6.5 lg genomic DNA per cell line was used for kinome sequencing. Cell lines used were 4 SCLC lines (DMS53, NCI-H69, SHP77, and NCI-H889), five NSCLC lines (NCI-H23, NCI-H460, NCI-H1155, NCI-H358, and NCI-H727), and one normal control (IMR90). Briefly, genomic DNA specimens were enriched for targeted sequences using SureSelect Human Kinome Kit (Agilent Technologies, Santa Clara, CA). The sequencing targets were 612 genes, encoding 517 protein kinases, 12 phosphatidylinositol 3-kinase (PI3 K) domain-containing genes, 12 diglyceride kinases, 6 PI3 K regulatory components, 9 inositol polyphosphate kinases, 9 phosphatidylinositol phosphate (PIP)4/ PIP5 kinases, 46 cancer related genes, and associated untranslated regions (Supplemental Table 1 ). Exon-enriched libraries were then sequenced using the Illumina highthroughput Genome Analyzer IIx sequencing system (Illumina, San Diego, CA) at the facility of Expression Analysis (Durham, NC). Analysis of sequence data was performed by Expression Analysis.
Immunoblot analysis
Cells were lysed in 62.5 mM Tris (pH 6.8)/2 % sodium dodecyl sulfate mixed with the protease inhibitor cocktail (Sigma, St. Louis, MO) and briefly sonicated before determining the protein concentration using the bicinchoninic acid reagent (Pierce, Rockford, IL). 40 lg of protein was resolved by SDS-PAGE and transferred to a polyvinylidene difluoride membrane filter (Bio-Rad, Hercules, CA). Membrane filters were blocked in 0.1 M Tris (pH 7.5)/0.9 % NaCl/0.05 % Tween 20 with 5 % nonfat dry milk and incubated with the appropriate antibodies. Antibodies were diluted as follows: neuron specific enolase (NSE), 1:2000 (Thermo Scientific, Rockford, IL); RET, 1:1000 (Santa Cruz Biotechnology, Santa Cruz, CA); phospho-RET (Tyr1062), 1:1000 (R&D Systems, Minneapolis, MN); poly(ADP-ribose) polymerase (PARP), 1:1000; B cell lymphoma 2 (Bcl-2), 1:2000; cleaved lamin A, 1:2000 (Cell Signaling Biotechnology, Danvers, MA); b-actin, 1:15000 (Sigma). The Supersignal West Femto and Pico chemiluminescence kits (Pierce) were used for visualization of the signal. Images of immunoblots were taken and processed using ChemiDoc XRS ? and Image Lab version 3.0 (Bio-Rad).
Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR was performed by reverse transcription of 1 lg total RNA isolated using Trizol (Invitrogen) and the subsequent 30 cycles of PCR using Taq polymerase (Invitrogen), as described elsewhere (Wu et al. 2013) . To detect RET splicing variant 2 (RET51), AGGGGCGGAAGATGAAGA and ACCTTTCA-CAAAGAAATGTTAACTATC were used. To detect RET splicing variant 4 (RET9), AGGGGCGGAAGATGAAGA and TGCAGAGGGGACAGCGGTGCTAGAA were used. As a control, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was amplified using CGGAGTCAACGGATTTG GTCGTAT and AGCCTTCTCCATGGTGGTGAAGAC.
Genotyping the RET polymorphism rs1799939
To determine the genotype at the locus of G691S RET (SNP rs1799939), a 302 base pair region in exon 11 of RET was amplified by PCR using TGGCGGTGCCAAGCCTC ACACCAC and GACCCTCACCAGGATCTTGAAGGC. The PCR products were run on 2 % agarose gel electrophoresis and were extracted for purification using GeneJET Gel Extraction Kit (Fisher Scientific-USA, Pittsburgh, PA). Approximately 50 ng of purified PCR products were sequenced using ATCCACTGTGCGACGAGC at Retrogen (San Diego, CA).
Statistical analysis
Genotype frequencies in the tested cell lines and the reference population were compared using multivariate logistic regression analysis for the co-dominant, dominant and recessive models. These analyses were performed using SNPStat (Sole et al. 2006) . Allelic frequencies were compared using the Fisher's exact test (Preacher and Briggs 2001) . The odds ratios (OR) and 95 % confidence intervals (CI) were calculated using the online statistical Fig. 1 Comparison of genes identified by this study (Sosonkina et al.) and two other studies Rudin et al. 2012) . Genes mutated in lung cancer cell lines were compared with the genes mutated in SCLC patients. 82 common genes that harbor identical or different mutations are listed. These mutations are described in Supplemental Table 2 Genes Genom (2014) 36:829-841 831 Table 1 The 31 genes harboring identical or closely located mutations detected in this study and in one or two reference studies Peifer et al. (2012) and Rudin et al. (2012) Gene Location 
Results
Kinome sequencing of human lung cancer cell lines
To identify kinase mutations associated with NE lung cancer, we performed exome sequencing of 517 protein kinases, 12 PI3 K domain-containing genes, 12 diglyceride kinases, 6 PI3 K regulatory components, 9 inositol polyphosphate kinases, 9 PIP4/PIP5 kinases, and 46 cancer related genes (Supplemental Table 1 ) in four SCLC and five NSCLC cell lines. Among these cell lines, all SCLC and two NSCLC (NCI-H1155 and NCI-H727) cell lines were previously characterized as NE tumors (Carney et al. 1985; Gazdar and Minna 1996; Linnoila 1996) . Our kinome sequencing revealed a number of mutations, and those genes that exhibit nonsynonymous or frameshift mutations in at least one cell line are listed in the Supplemental Table 2 . This sequencing also detected many mutations previously reported in these cell lines, which validates cell line identity (Supplemental Table 3 ).
To determine the extent of overlap between our data and the data of other studies, we compared our results with the studies of genome-wide mutation profiles in SCLC patients conducted by Rudin et al. (2012) and Peifer et al. (2012) . Although harboring different mutations, 160 kinase genes were commonly identified by us and Rudin et al. (2012) , while 172 kinase genes were commonly identified by us and Peifer et al. (2012) . Among these, 82 genes were common to all three studies (Fig. 1) , of which 31 genes harbored different mutations in the same or adjacent exons in at least two studies (Table 1 ). Seven of these 31 genes exhibit identical (2012) and Rudin et al. (2012) . These mutations are
, and VRK2 Y187F (Table 1) . However, these mutations were not present in the lung cancer lines examined in this study. Of note, we found that NCI-H460 harbors PIK3CA E545K , which was also detected in SCLC patients by Rudin et al. (2012) but not by Peifer et al. (2012) (Table 1 ). These data demonstrate that different human lung cancer lines harbor various mutations in the kinase-encoding genes.
In addition to the mutations above, we also found two non-synonymous mutations in the RET proto-oncogene. Intriguingly, the NE lung tumor lines, DMS53, NCI-H69, SHP77, NCI-H1155, and NCI-H727, exhibited a common polymorphism (rs1799939), which substitutes GGT (Gly) to AGT (Ser) at codon 691 in the protein juxta-membrane domain (Table 1 ). However, this mutation was not detected in any of the tested non-NE tumor lines, although NCI-H23 exhibited CGC (Arg) to CTC (Leu) substitution at codon 77 in the extracellular domain of RET, as previously reported (Abaan et al. 2013 ) (Table 1) .
G691S RET variant is relatively frequent in NE lung cancer lines
Detection of G691S RET variant led us to further evaluate the genetic variation in in NE lung cancer cell lines. First, we verified the RET kinome sequencing results from the 9 lung cancer lines by sequencing their RET exon 11 region using PCR and the Sanger method. Besides, we also analyzed three additional SCLC and three additional NSCLC cell lines. This 2nd sequencing analysis confirmed the initial sequencing results and, furthermore, identified additional cell lines that harbor G691S RET variant (Table 2 ; Supplemental Fig. 1 ). In these 15 cell lines, overall frequency of the G691S allele (the ''A allele'' of the RET SNP rs1799939) was 43.3 %, while NE and non-NE lines exhibited 60 and 10 % of G691S allele frequency, respectively (Table 3) . Importantly, the A allele frequency in 10 NE lines was significantly different from the allele frequency in the reference population (p = 0.0001), which is 17.6 % according to the NCBI SNP database (see Materials and Methods for details). However, the A allele frequency in the 5 non-NE lung tumor lines was not significantly different from the allele frequency in the reference population (p = 1.0). We next analyzed the genotypes distribution at rs1799939 (i.e., AA, GA, and GG) in lung cell lines in comparison with the reference population (Table 4) . We found that the frequency of AA genotype is significantly higher in lung cell lines than in the reference population (p = 0.0011) whereas the frequency of GA genotype was not significantly different (Table 4 ). These data suggest that the G691S allele may be present more frequently in lung cancer, especially lung NE tumors, than in general population.
RET expression is not correlated with NSE expression in lung tumor lines
The correlation between the G691S RET variant and NE lung tumor lines led us to investigate whether expression of RET (wild type and RET G691S ), at mRNA and protein levels, is correlated with the levels of NSE in lung cancer cell lines. NSE is a key NE marker (Kasprzak et al. 2007) , which is strongly expressed in NE lung tumor lines (Fig. 2a) . As determined by RT-PCR of the RET splicing variants 2 (RET51) and 4 (RET9), and by Western blotting of RET (total and phosphorylated at Tyr1062), our analyses did not reveal any correlation between the levels of RET and NSE (Fig. 2) . Therefore, although G691S RET mutation is correlated with NE lung tumor lines, expression levels of RET or RET G691S are heterogenous in the tumor lines.
We also investigated whether the receptor tyrosine kinase inhibitors, vandetanib (trade name Caprelsa, AstraZeneca) and cabozantinib (trade name Cometriq, Exelixis) could affect NSE expression in NCI-H209, NCI-H1155, and NCI-H125 cells, because these NSE-positive cell lines exhibited relatively high levels of RET autophosphorylation at Tyr1062, an indication of RET activation (Asai et al. 2006) , and because vandetanib and cabozantinib can inhibit RET along with other receptor tyrosine kinases activated by vascular endothelial growth factor, epidermal growth factor, or hepatocyte growth factor (Carlomagno et al. 2002; Wedge et al. 2002; Yakes et al. 2011 ). In our analysis, neither of these inhibitors affected NSE levels in cells, although these inhibitors induced expected effects in these cell lines, i.e., downregulated RET activity, as indicated by RET autophosphorylation at Tyr1062, and suppressed cell survival, as indicated by altered expression levels of lamin A, Bcl-2, or PARP (Supplemental Fig. 2 ). These data suggest that RET may not be involved in the maintenance of NE phenotype in lung cancer.
Discussion
Currently, no effective therapeutic modalities are available for the treatment of NE lung tumors. Particularly, SCLC is rarely treated by surgery due to its early metastasis and extensiveness at first diagnosis (van Meerbeeck et al. 2011) . While this demands better understanding of the molecular alterations underlying NE lung tumors, this also limits the procurement of suitable fresh-frozen tumor specimens. Therefore, cell lines are an indispensable model for the study of these diseases. In this regard, genomic profiles of human lung tumor cell lines are important information for the design of future research, especially now that the genomic profiles of human lung tumors from patients are becoming available. We expect that the catalog of kinase genes whose alterations were analyzed in comparison with the results of two other integrative analyses of SCLC Rudin et al. 2012 ) may facilitate the usage of the cell lines examined in our study as a model for the identification and characterization of putative oncogenic mutations. Of note, although their mutations were not identical, 31 kinase-encoding and other cancerrelated genes were commonly detected by this study as well as by the two previous studies Rudin et al. 2012 ).
In the human lung tumor cell lines, we detected two RET mutations, RET G691S and RET R77L . Our data suggest that the G691S RET SNP (c.2071G [ A) may be associated with NE lung tumors. Intriguingly, G691 RET variant was reported only in one SCLC patient (Futami et al. 2003) , but it was not reported in the studies of recent genome wide mutational analyses Pleasance et al. 2010; Rudin et al. 2012; Sos et al. 2012) . It is possible that this polymorphism was overlooked in those studies because common polymorphisms are regarded as less significant than a novel mutation. Because allelic variation can be associated with the susceptibility to a certain disease, further analysis of G691S RET SNP in a larger scale is necessary to determine the significance of the RET polymorphism in NE lung tumor.
In addition to its association with a few tumor types featuring the phenotypes relevant to NE characteristics (Barr et al. 2012; Cardot-Bauters et al. 2008; Elisei et al. 2004; Narita et al. 2009; Sawai et al. 2005) , G691S RET variant has been suspected for its role in tumorigenesis as a genetic modifier, particularly in MEN2A (Robledo et al. 2003) . It is therefore conceivable that the G691S RET variant may also have a role in NE lung tumorigenesis. Nevertheless, our data did not reveal any correlation between the expression levels of RET, both mRNA and protein, and NSE. Moreover, the multi-receptor tyrosine kinase inhibitors, vandetanib and cabozantinib, did not affect the levels of NSE in the NE lung tumor lines expressing active RET, although the inhibitors suppressed RET activity. Given these data, RET does not appear to be necessary for the maintenance of NE phenotype in lung cancers. Nevertheless, it is possible that G691S RET mutation has a specific role at an early stage of NE lung carcinogenesis but, afterward, its role becomes unnecessary. Fig. 2 Expression of RET in lung cancer cell lines. a total cell lysates of lung cancer lines maintained in RPMI medium supplemented with 10 % fetal bovine serum were analyzed by Western blotting for phosphorylated RET (p-RET), RET, and NSE expression. GAPDH is the loading control. b total RNA extracted from the lung cancer cell cultures in (a) were examined by RT-PCR for expression of RET splicing variants 2 and 4. GAPDH is the control for use of equal amount of RNA for PCR
Conclusion
Our study provides the kinome sequencing results of human lung tumor cell lines, which may help facilitate future research using these cell lines. Our data suggest a potential association of G691S RET polymorphism with NE lung tumor, proposing the necessity of more thorough evaluation of this possibility.
